Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of four doses of PRO-118 ophthalmic solution ophthalmic solution compared with placebo, for the treatment of seasonal (SAC) and perennial (PAC) allergic conjunctivitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

NCT01657240

Allergic Conjunctivitis

WITHDRAWN PHASE3

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

NCT03521791

Pterygium Ocular Pain Ocular Inflammation +1 more

COMPLETED PHASE4

Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects

NCT03519516

Conjunctivitis Conjunctivitis, Bacterial

COMPLETED PHASE1

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.

NCT03698045

Conjunctivitis, Bacterial

WITHDRAWN PHASE1

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

NCT00882687

Allergic Conjunctivitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A phase II, double-masked, randomized, placebo-controlled, parallel-group and multicenter clinical trial, to evaluate and compared the clinical efficacy and safety of four doses of PRO-118 ophthalmic solution ( PRO-118 0.015% qd, PRO-118 0.015% twice daily , PRO-118 0.020% qd, PRO-118 0.020% twice daily) for the treatment of seasonal (SAC) and perennial (PAC) allergic conjunctivitis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Itching Ocular Allergy Seasonal Allergic Conjunctivitis Perennial Allergic Conjunctivitis Conjunctivitis, Allergic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A. PRO-118/Placebo 0.015%,0.020%

Group Type EXPERIMENTAL

PRO-118 Ophthalmic Solution 0.015%

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days

Arm B. PRO-118/Placebo 0.015%,0.020%

Group Type EXPERIMENTAL

PRO-118 Ophthalmic Solution 0.015 %

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days

Arm C. PRO-118/Placebo 0.015%,0.020%

Group Type EXPERIMENTAL

PRO-118 Ophthalmic Solution 0.020 %

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days

Arm D. PRO-118/Placebo 0.015%,0.020%

Group Type EXPERIMENTAL

PRO-118 Ophthalmic Solution 0.020 %

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days

Arm E PRO-118/Placebo 0.015%,0.020%

Group Type PLACEBO_COMPARATOR

Placebo Ophthalmic Solution

Intervention Type DRUG

Placebo Ophthalmic Solution applied qd during 21 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRO-118 Ophthalmic Solution 0.015%

PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.015 %

PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.020 %

PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days

Intervention Type DRUG

PRO-118 Ophthalmic Solution 0.020 %

PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days

Intervention Type DRUG

Placebo Ophthalmic Solution

Placebo Ophthalmic Solution applied qd during 21 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with diagnosis of seasonal or perennial allergic conjunctivitis.
* Age ≥ 6 years old at screening visit.
* Male or female patients.

Applicable in patients ≥ 18 years old.

* Patient has signed the Informed Consent Form (ICF) prior to any screening procedures.

Applicable in patients with age ≤ 18 years old.

* Patients Patients'parents or legal guardians signed an Informed Consent Form (ICF).
* The patients also provided written assent.

Exclusion Criteria

* Presence of any form of allergic conjunctivitis other than seasonal or perennial allergic conjunctivitis (Atopic keratoconjunctivitis, giant papillary conjunctivitis).
* Any other ophthalmic medication within seven days prior to randomization.
* Patient with one blind eye.
* Visual acuity of 20/40 in any eye.
* Patients with history of active stage of any other concomitant ocular disease.
* Contraindications or sensitivity to any component of the study treatments.
* Contact lens users.
* Ocular surgery within the past 3 months.
* Women who were not using an effective means of contraception or who were pregnant or nursing.
* Participation in any studies of investigational drugs within 90 days previous to the inclusion.

Discontinuation criteria:

* Patients could be discontinued before the completion of the study because of use of prohibited medications, adverse events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No